With regard to GITR activation, a clinical grade of anti-GITR agonistic mAb is beingtested in a phase I clinical trial [28], and GITRL fusion proteins have also shown a promising antitumor potential inpreclinical tumor models [25]. Here, TNFRSF18 is linked to neoplasm.